DECR2 Inhibitors
DECR2 inhibitors target various facets of fatty acid metabolism, thereby modulating DECR2 function, a crucial enzyme in the mitochondrial fatty acid beta-oxidation pathway. Compounds like Etomoxir and Perhexiline exhibit direct inhibitory action on the carnitine palmitoyltransferase-1, a gatekeeper enzyme for the entry of long-chain fatty acids into the mitochondria. By impeding this process, these inhibitors can indirectly limit the substrates available for DECR2 action.
Agents like Nicotinamide, which inhibit sirtuins, shed light on the intricate interplay of energy metabolism and fatty acid oxidation, showcasing how broad metabolic modulation can trickle down to affect specialized enzymes like DECR2. The realm of DECR2 inhibitors, thus, covers a diverse landscape of compounds that influence the broader metabolic framework, orchestrating potential shifts in the specific function and role of DECR2 in fatty acid beta-oxidation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R-(+)-Etomoxir | 124083-20-1 | sc-208201A sc-208201 | 2 mg 5 mg | $245.00 $430.00 | ||
Directly inhibits carnitine palmitoyltransferase-1 (CPT-1), blocking the transfer of fatty acids into mitochondria for beta-oxidation. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $184.00 | ||
Inhibits mitochondrial carnitine palmitoyltransferase, influencing the beta-oxidation process, potentially affecting DECR2's function. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $51.00 | 7 | |
Lipase inhibitor. By blocking lipid digestion, it indirectly affects fatty acid metabolism and its subsequent pathways. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $43.00 $65.00 $200.00 $815.00 | 6 | |
Inhibits sirtuins, which play roles in fatty acid oxidation and energy metabolism, potentially influencing DECR2 activity. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
PPARα antagonist. Given DECR2's role in fatty acid metabolism, PPARα modulation can influence DECR2's activity. | ||||||
Acipimox | 51037-30-0 | sc-203497 sc-203497A | 50 mg 100 mg | $77.00 $128.00 | ||
Reduces serum free fatty acids, indirectly influencing fatty acid metabolism pathways and potentially DECR2 function. | ||||||
Atglistatin | 1469924-27-3 | sc-503147 | 5 mg | $330.00 | ||
Inhibits adipose triglyceride lipase, influencing lipid catabolism and potentially modulating DECR2 activity. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $149.00 $826.00 | 14 | |
Inhibits long-chain acyl-CoA synthetase, affecting fatty acid metabolism and potentially DECR2 function. | ||||||